PRME AGRITECH- ONLINE SHOP

Koselugo is used to treat neurofibromatosis type 1 (NF1) in children aged 2 years and older who have symptomatic, inoperable plexiform neurofibromas (PN). It is an oral capsule taken twice a day.

Koselugo works by targeting a specific cellular signalling pathway that is overactive in children with NF1. A genetic mutation, leads to overactivity of the RAF-MEK-ERK signaling pathway, which normally controls cell growth and division. When it is stuck in the "on" position, it causes uncontrollable cell growth, forming the benign tumors called neurofibromas that are characteristic of NF1. Koselugo specifically blocks MEK1 and MEK2 proteins, key switches in the middle of the overactive pathway. This breaks this chain of communication, blocking the signal for excessive cell growth. Koselugo (selumetinib) is a kinase inhibitor.